Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-Daco prophylactic skin toxicity management in EGFR-mutated NSCLC
jRCTs071190015Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Incidence of grade ≥2 skin toxicities during first 8 weeks. Started Nov 2019; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071190015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190015.